Adjuvant chemotherapy for stage III colon cancer in the oldest old: Results beyond clinical guidelines

Anasooya Abraham, Elizabeth B Habermann, David A. Rothenberger, Mary Kwaan, Armin D. Weinberg, Helen M. Parsons, Pankaj Gupta, Waddah B. Al-Refaie

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: Randomized trials demonstrating the benefits of chemotherapy in patients with American Joint Committee on Cancer stage III colon cancer underrepresent persons aged ≥ 75 years. The generalizability of these studies to a growing elderly population remains unknown. Methods: Using the California Cancer Registry for 1994 through 2008, the authors conducted a population-based study of postcolectomy patients aged 50 years to 94 years with stage III (N1M0) colon adenocarcinoma. A 2-sided chi-square test and Cochran-Armitage test for trend were used to compare patient and tumor characteristics associated with receipt of chemotherapy across age groups. Multivariate regression was used to assess the association between older age and receipt of chemotherapy. Kaplan-Meier Methods and Cox proportional hazards modeling were used to evaluate the association between chemotherapy and mortality, with propensity score adjustment. Results: Approximately 44% (12,382 patients) of the study cohort was aged ≥ 75 years. Persons aged ≥ 75 years were found to be less likely to have received adjuvant chemotherapy than those aged < 75 years (30% vs 68% in patients aged 50 years-74 years; P <.0001). On multivariate analysis, patients aged 75 years to 84 years were 13 times less likely, and those aged 85 years to 94 years were 24 times less likely, to have received chemotherapy as patients aged 50 years to 64 years. Nevertheless, age-stratified multivariate survival analyses indicated that chemotherapy provided comparable mortality reduction across age groups. Conclusions: The percentage of persons aged ≥ 75 years receiving adjuvant chemotherapy remains low despite demonstrated survival benefits. These findings deserve attention within the context of a patient's life expectancy, underlying comorbidities, and performance status, as well as clinician bias. The Results of the current study support the call for phase II/III studies assessing the toxicities and benefits of adjuvant chemotherapy for the treatment of stage III colon cancer in the elderly.

Original languageEnglish (US)
Pages (from-to)395-403
Number of pages9
JournalCancer
Volume119
Issue number2
DOIs
StatePublished - Jan 15 2013
Externally publishedYes

Fingerprint

Adjuvant Chemotherapy
Colonic Neoplasms
Guidelines
Drug Therapy
Multivariate Analysis
Age Groups
Neoplasms
Propensity Score
Mortality
Chi-Square Distribution
Survival Analysis
Life Expectancy
Population
Registries
Comorbidity
Colon
Adenocarcinoma
Cohort Studies
Survival

Keywords

  • age disparities
  • chemotherapy
  • colon cancer
  • elderly cancer care

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Abraham, A., Habermann, E. B., Rothenberger, D. A., Kwaan, M., Weinberg, A. D., Parsons, H. M., ... Al-Refaie, W. B. (2013). Adjuvant chemotherapy for stage III colon cancer in the oldest old: Results beyond clinical guidelines. Cancer, 119(2), 395-403. https://doi.org/10.1002/cncr.27755

Adjuvant chemotherapy for stage III colon cancer in the oldest old : Results beyond clinical guidelines. / Abraham, Anasooya; Habermann, Elizabeth B; Rothenberger, David A.; Kwaan, Mary; Weinberg, Armin D.; Parsons, Helen M.; Gupta, Pankaj; Al-Refaie, Waddah B.

In: Cancer, Vol. 119, No. 2, 15.01.2013, p. 395-403.

Research output: Contribution to journalArticle

Abraham, A, Habermann, EB, Rothenberger, DA, Kwaan, M, Weinberg, AD, Parsons, HM, Gupta, P & Al-Refaie, WB 2013, 'Adjuvant chemotherapy for stage III colon cancer in the oldest old: Results beyond clinical guidelines', Cancer, vol. 119, no. 2, pp. 395-403. https://doi.org/10.1002/cncr.27755
Abraham, Anasooya ; Habermann, Elizabeth B ; Rothenberger, David A. ; Kwaan, Mary ; Weinberg, Armin D. ; Parsons, Helen M. ; Gupta, Pankaj ; Al-Refaie, Waddah B. / Adjuvant chemotherapy for stage III colon cancer in the oldest old : Results beyond clinical guidelines. In: Cancer. 2013 ; Vol. 119, No. 2. pp. 395-403.
@article{304f9a6f1b514558bc999f8a1640a813,
title = "Adjuvant chemotherapy for stage III colon cancer in the oldest old: Results beyond clinical guidelines",
abstract = "Background: Randomized trials demonstrating the benefits of chemotherapy in patients with American Joint Committee on Cancer stage III colon cancer underrepresent persons aged ≥ 75 years. The generalizability of these studies to a growing elderly population remains unknown. Methods: Using the California Cancer Registry for 1994 through 2008, the authors conducted a population-based study of postcolectomy patients aged 50 years to 94 years with stage III (N1M0) colon adenocarcinoma. A 2-sided chi-square test and Cochran-Armitage test for trend were used to compare patient and tumor characteristics associated with receipt of chemotherapy across age groups. Multivariate regression was used to assess the association between older age and receipt of chemotherapy. Kaplan-Meier Methods and Cox proportional hazards modeling were used to evaluate the association between chemotherapy and mortality, with propensity score adjustment. Results: Approximately 44{\%} (12,382 patients) of the study cohort was aged ≥ 75 years. Persons aged ≥ 75 years were found to be less likely to have received adjuvant chemotherapy than those aged < 75 years (30{\%} vs 68{\%} in patients aged 50 years-74 years; P <.0001). On multivariate analysis, patients aged 75 years to 84 years were 13 times less likely, and those aged 85 years to 94 years were 24 times less likely, to have received chemotherapy as patients aged 50 years to 64 years. Nevertheless, age-stratified multivariate survival analyses indicated that chemotherapy provided comparable mortality reduction across age groups. Conclusions: The percentage of persons aged ≥ 75 years receiving adjuvant chemotherapy remains low despite demonstrated survival benefits. These findings deserve attention within the context of a patient's life expectancy, underlying comorbidities, and performance status, as well as clinician bias. The Results of the current study support the call for phase II/III studies assessing the toxicities and benefits of adjuvant chemotherapy for the treatment of stage III colon cancer in the elderly.",
keywords = "age disparities, chemotherapy, colon cancer, elderly cancer care",
author = "Anasooya Abraham and Habermann, {Elizabeth B} and Rothenberger, {David A.} and Mary Kwaan and Weinberg, {Armin D.} and Parsons, {Helen M.} and Pankaj Gupta and Al-Refaie, {Waddah B.}",
year = "2013",
month = "1",
day = "15",
doi = "10.1002/cncr.27755",
language = "English (US)",
volume = "119",
pages = "395--403",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Adjuvant chemotherapy for stage III colon cancer in the oldest old

T2 - Results beyond clinical guidelines

AU - Abraham, Anasooya

AU - Habermann, Elizabeth B

AU - Rothenberger, David A.

AU - Kwaan, Mary

AU - Weinberg, Armin D.

AU - Parsons, Helen M.

AU - Gupta, Pankaj

AU - Al-Refaie, Waddah B.

PY - 2013/1/15

Y1 - 2013/1/15

N2 - Background: Randomized trials demonstrating the benefits of chemotherapy in patients with American Joint Committee on Cancer stage III colon cancer underrepresent persons aged ≥ 75 years. The generalizability of these studies to a growing elderly population remains unknown. Methods: Using the California Cancer Registry for 1994 through 2008, the authors conducted a population-based study of postcolectomy patients aged 50 years to 94 years with stage III (N1M0) colon adenocarcinoma. A 2-sided chi-square test and Cochran-Armitage test for trend were used to compare patient and tumor characteristics associated with receipt of chemotherapy across age groups. Multivariate regression was used to assess the association between older age and receipt of chemotherapy. Kaplan-Meier Methods and Cox proportional hazards modeling were used to evaluate the association between chemotherapy and mortality, with propensity score adjustment. Results: Approximately 44% (12,382 patients) of the study cohort was aged ≥ 75 years. Persons aged ≥ 75 years were found to be less likely to have received adjuvant chemotherapy than those aged < 75 years (30% vs 68% in patients aged 50 years-74 years; P <.0001). On multivariate analysis, patients aged 75 years to 84 years were 13 times less likely, and those aged 85 years to 94 years were 24 times less likely, to have received chemotherapy as patients aged 50 years to 64 years. Nevertheless, age-stratified multivariate survival analyses indicated that chemotherapy provided comparable mortality reduction across age groups. Conclusions: The percentage of persons aged ≥ 75 years receiving adjuvant chemotherapy remains low despite demonstrated survival benefits. These findings deserve attention within the context of a patient's life expectancy, underlying comorbidities, and performance status, as well as clinician bias. The Results of the current study support the call for phase II/III studies assessing the toxicities and benefits of adjuvant chemotherapy for the treatment of stage III colon cancer in the elderly.

AB - Background: Randomized trials demonstrating the benefits of chemotherapy in patients with American Joint Committee on Cancer stage III colon cancer underrepresent persons aged ≥ 75 years. The generalizability of these studies to a growing elderly population remains unknown. Methods: Using the California Cancer Registry for 1994 through 2008, the authors conducted a population-based study of postcolectomy patients aged 50 years to 94 years with stage III (N1M0) colon adenocarcinoma. A 2-sided chi-square test and Cochran-Armitage test for trend were used to compare patient and tumor characteristics associated with receipt of chemotherapy across age groups. Multivariate regression was used to assess the association between older age and receipt of chemotherapy. Kaplan-Meier Methods and Cox proportional hazards modeling were used to evaluate the association between chemotherapy and mortality, with propensity score adjustment. Results: Approximately 44% (12,382 patients) of the study cohort was aged ≥ 75 years. Persons aged ≥ 75 years were found to be less likely to have received adjuvant chemotherapy than those aged < 75 years (30% vs 68% in patients aged 50 years-74 years; P <.0001). On multivariate analysis, patients aged 75 years to 84 years were 13 times less likely, and those aged 85 years to 94 years were 24 times less likely, to have received chemotherapy as patients aged 50 years to 64 years. Nevertheless, age-stratified multivariate survival analyses indicated that chemotherapy provided comparable mortality reduction across age groups. Conclusions: The percentage of persons aged ≥ 75 years receiving adjuvant chemotherapy remains low despite demonstrated survival benefits. These findings deserve attention within the context of a patient's life expectancy, underlying comorbidities, and performance status, as well as clinician bias. The Results of the current study support the call for phase II/III studies assessing the toxicities and benefits of adjuvant chemotherapy for the treatment of stage III colon cancer in the elderly.

KW - age disparities

KW - chemotherapy

KW - colon cancer

KW - elderly cancer care

UR - http://www.scopus.com/inward/record.url?scp=84872060348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872060348&partnerID=8YFLogxK

U2 - 10.1002/cncr.27755

DO - 10.1002/cncr.27755

M3 - Article

C2 - 22806931

AN - SCOPUS:84872060348

VL - 119

SP - 395

EP - 403

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -